

### Client Information (required)

Client Name		
Client Account No.		
Client Phone	Client Order No.	
Address		
City	State	Zip Code

### Submitting Provider/Provider Name Information (required)

Submitting/Referring Provider (Last, First)
<b>Fill in only if Call Back is required.</b> Phone ( ) _____ - _____ Fax* ( ) _____ - _____
Provider's National I.D. (NPI)

\*Fax number given must be from a fax machine that complies with applicable HIPAA regulation.

### Pathologist's Name (required)

Submitting/Referring Pathologist (Last, First)
Phone ( ) _____ - _____ Fax* ( ) _____ - _____

\*Fax number given must be from a fax machine that complies with applicable HIPAA regulation.

### New York State Patients: Informed Consent for Genetic Testing

"I hereby confirm that informed consent has been signed by an individual legally authorized to do so and is on file with this office or the individual's provider's office."

Signature \_\_\_\_\_

**Note:** It is the client's responsibility to maintain documentation of the order.

<b>MML Internal Use Only</b>
------------------------------

### Ship specimens to:

Mayo Medical Laboratories  
3050 Superior Drive NW  
Rochester, MN 55901

**Customer Service: 855-516-8404**

Visit [www.MayoMedicalLaboratories.com](http://www.MayoMedicalLaboratories.com) for the most up-to-date test and shipping information.

### Patient Information (required)

Patient ID (Medical Record No.)	
Patient Name (Last, First, Middle)	
Gender <input type="checkbox"/> Male <input type="checkbox"/> Female	Birth Date (Month DD, YYYY)
Collection Date (Month DD, YYYY)	Time <input type="checkbox"/> a.m. <input type="checkbox"/> p.m.

### Specimens Provided (required)

<input type="checkbox"/> Blood <input type="checkbox"/> Bone Marrow <input type="checkbox"/> Fixed Cells <input type="checkbox"/> Cultured Cells <input type="checkbox"/> DNA <input type="checkbox"/> Lymph Node <input type="checkbox"/> Spleen	<input type="checkbox"/> Paraffin block No. sent: _____ Indicate source: <input type="checkbox"/> Slides No. sent: _____	<input type="checkbox"/> Tissue No. sent: _____ <input type="checkbox"/> Frozen <input type="checkbox"/> Fixed Formalin <input type="checkbox"/> Wet Tissue <input type="checkbox"/> Other Fixative type: _____ <input type="checkbox"/> Other Anatomic site: _____
---	--	---

CBC results:

HB _____	RBC _____	WBC _____
HCT _____	MCV _____	PLT _____

### If ordering HER2 testing:

Was specimen fixed in 10% neutral buffered formalin within 1 hour from surgical collection time?  
 Yes  No

Has specimen been fixed in 10% neutral buffered formalin for 6 to 72 hours?  
 Yes  No

### Pathology/Clinical Diagnosis (required)

(Include a brief history, pertinent laboratory results, suspected diagnosis, and reason for referral.)

  
  
  
  
  
  
  
  
  
  
  

ICD-10 Diagnosis Code

### Billing Information

- An itemized invoice will be sent each month.
- Payment terms are net 30 days.

Call the Business Office with billing related questions:  
 800-447-6424 (US and Canada)  
 507-266-5490 (outside the US)

## Patient Information (required)

Patient ID (Medical Record No.)	Client Account No.
Patient Name (Last, First, Middle)	Client Order No.
Birth Date (Month DD, YYYY)	

**PATHOLOGY**

PATHC Pathology Consultation  
Appropriate stains and ancillary testing may be performed in order to render an accurate diagnosis

**SPECIAL TESTING**

**PD-L1 Immunohistochemical stains**

PDL1 PD-L1 (SP263), Semi-Quantitative Immunohistochemistry, Manual

PDL1S PD-L1 (SP142), Semi-Quantitative Immunohistochemistry, Manual

PDL12 PD-L1 (22C3), Semi-Quantitative Immunohistochemistry, Manual

**Microsatellite Instability (MSI)/Mismatch Repair**

MSIHC Microsatellite Instability (MSI)/Immunohistochemistry (IHC) Profile-Lynch/Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Screen

MSI Microsatellite Instability (MSI), Tumor

IHC Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor

**Chromosome Analysis**

CHRBF Chromosome Analysis, Body Fluid

CHRST Chromosome Analysis, Solid Tumors

**Next-Generation Sequencing (NGS) Panels**

GISTP GIST-Targeted Gene Panel by Next-Generation Sequencing, Tumor

LNGPR Lung Cancer-Targeted Gene Panel with Rearrangement, Tumor (mutations and rearrangements)

MELP Melanoma Targeted Gene Panel by Next-Generation Sequencing, Tumor

NONTP Neuro-Oncology Panel, Tumor

RASFP RAS/RAF Targeted Gene Panel by Next-Generation Sequencing, Tumor

CAPN Solid Tumor Targeted Cancer Gene Panel by Next-Generation Sequencing

**Chromosomal Microarray**

CMAPT Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded

CMAT Chromosomal Microarray, Tumor, Fresh or Frozen using Affymetrix Cytoscan HD

**MATE PAIR SEQUENCING**

MTRTI MatePair, Targeted Rearrangements, Oncology

**PATHOLOGY: TARGETED TUMOR TESTING**

**Bone and Soft Tissue**

FOXOF Alveolar Rhabdomyosarcoma (ARMS), 13q14 (FOXO1 or FKHR) Rearrangement, FISH, Tissue

ETV6F ETV6 (12p13.2) Rearrangement, FISH, Tissue

ARMS Alveolar Rhabdomyosarcoma by Reverse Transcriptase PCR (RT-PCR)

TFE3F Alveolar Soft Part Sarcoma (ASPS)/Renal Cell Carcinoma (RCC), Xp11.23 (TFE3), FISH, Tissue

MASF Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue

CTNNB Beta-Catenin (CTNNB1) Mutation Analysis, Tumor

DSRCT Desmoplastic Small Round-Cell Tumor by Reverse Transcriptase PCR (RT-PCR)

ESTUF Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE) Rearrangement, FISH, Tissue

EWSF Ewing Sarcoma (EWS), 22q12 (EWSR1) Rearrangement, FISH, Tissue

EWS Ewing Sarcoma, by Reverse Transcriptase PCR (RT-PCR)

IMTF Inflammatory Myofibroblastic Tumors (IMT), 2p23 (ALK) Rearrangement, FISH, Tissue

KIT8 KIT Exon 8, Mutation Analysis

KIT9 KIT Exon 9, Mutation Analysis

KIT11 KIT Exon 11, Mutation Analysis

KIT13 KIT Exon 13, Mutation Analysis

KIT17 KIT Exon 17, Mutation Analysis

FUSF Low-Grade Fibromyxoid Sarcoma (LGFMS), 16p11.2 (FUS or TLS) Rearrangement, FISH, Tissue

MDM2F MDM2 (12q15) Amplification, Well-Differentiated Liposarcoma/Atypical Lipomatous Tumor, FISH, Tissue

DDITF Myxoid/Round Cell Liposarcoma, 12q13 (DDIT3 or CHOP) Rearrangement, FISH, Tissue

MYCNF Neuroblastoma, 2p24 (MYCN) Amplification, FISH

PDG12 PDGFRA Exon 12, Mutation Analysis

PDG14 PDGFRA Exon 14, Mutation Analysis

PDG18 PDGFRA Exon 18, Mutation Analysis

PDGF PDGFB (22q13), Dermatofibrosarcoma Protuberans/Giant Cell Fibroblastoma, FISH, Tissue

SS18F Synovial Sarcoma (SS), 18q11.2 (SS18 or SYT) Rearrangement, FISH, Tissue

SYT Synovial Sarcoma by Reverse Transcriptase PCR (RT-PCR)

USPF USP6 (17p13), Aneurysmal Bone Cyst and Nodular Fasciitis, FISH, Tissue

**Breast**

MASF Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue

CTCBC Circulating Tumor Cells (CTC) for Breast Cancer by CellSearch, Blood

FGF1F FGFR1 (8p11.2) Amplification, FISH, Tissue

HER2F HER2 Amplification Associated with Breast Cancer, FISH, Tissue

ESR1 Estrogen Receptor 1 (ESR1) Mutation Analysis, Tumor

ETV6F ETV6 (12p13.2) Rearrangement, FISH, Tissue

**Immunohistochemical assays interpreted with digital image analysis**

ERPR Estrogen/Progesterone Receptor, Semi-Quantitative, Manual

KI67B Ki-67(MIB-1), Breast, Quantitative, Automated

HERBA Breast, Quantitative, Automated with HER2 FISH reflex

HERBN HER2, Breast, Quantitative, Automated, No Reflex

HERDM HER2, Breast, DCIS, Quantitative, Manual with HER2 FISH Reflex

HERDN HER2, Breast, DCIS, Quantitative, Manual No Reflex

**Gastrointestinal**

FBILM Biliary Tract Malignancy-Cytology, FISH

BRAFT BRAF Mutation Analysis (V600E), Tumor

CTCCC Circulating Tumor Cells (CTC) for Colorectal Cancer by CellSearch, Blood

EGFRT EGFR Gene, Mutation Analysis, 29 Mutation Panel, Tumor

PRKAF Fibrolamellar Carcinoma, 19p13.1 (PRKACA) Rearrangement, FISH, Tissue

FGFR2 FGFR2 (10q26.1) Rearrangement, FISH, Tissue

GISTP GIST-Targeted Gene Panel by Next-Generation Sequencing, Tumor

H2GEF HER2 Amplification Associated with Gastroesophageal Cancer, FISH, Tissue

HERGM HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual

HERGN HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual, No Reflex

## Patient Information (required)

Patient ID <i>(Medical Record No.)</i>	Client Account No.
Patient Name <i>(Last, First, Middle)</i>	Client Order No.
Birth Date <i>(Month DD, YYYY)</i>	

**Gastrointestinal (cont.)**

KINET Ki-67(MIB-1), Gastrointestinal/Pancreatic Neuroendocrine Tumors, Quantitative Immunohistochemistry, Automated

KIT8 KIT Exon 8, Mutation Analysis

KIT9 KIT Exon 9, Mutation Analysis

KIT11 KIT Exon 11, Mutation Analysis

KIT13 KIT Exon 13, Mutation Analysis

KIT17 KIT Exon 17, Mutation Analysis

KRASC KRAS Mutation Analysis, 7 Mutation Panel, Colorectal

METF MET (7q31), FISH, Tissue

ML1HM MLH1 Hypermethylation Analysis, Tumor

BRMLH MLH1 Hypermethylation and BRAF Mutation Analysis, Tumor

MSIHC Microsatellite Instability (MSI)/ Immunohistochemistry (IHC) Profile-Lynch/ Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Screen

IHC Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor

MSI Microsatellite Instability (MSI), Tumor

RASFP RAS/RAF Targeted Gene Panel by Next-Generation Sequencing, Tumor

**Genitourinary**

TFE3F Alveolar Soft Part Sarcoma (ASPS)/Renal Cell Carcinoma (RCC), Xp11.23 (TFE3), FISH, Tissue

CTCPC Circulating Tumor Cells (CTC) for Prostate Cancer by CellSearch, Blood

GCTF Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue

H2URF HER2 Amplification Associated with Urothelial Carcinoma, FISH, Tissue

FUR0C UroVysion for Detection of Bladder Cancer, Urine

NUT1F NUTM1 (15q14) Rearrangement, FISH, Tissue

PROF Prostate Tumor, FISH, Tissue

TFEFB Renal Cell Carcinoma, 6p21.1 (TFEB) Rearrangement, FISH, Tissue

**Gynecology**

**Endometrial/Uterine Carcinoma**

ESTUF Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE) Rearrangement, FISH, Tissue

ML1HM MLH1 Hypermethylation Analysis, Tumor

**Ovarian Carcinoma**

XL2 FOXL2 Mutation Analysis, Tumor

**Gestational/Trophoblastic Disease/ Molar Pregnancy**

POCF Products of Conception (POC) Aneuploidy Detection, FISH, Paraffin-Embedded Tissue

**Lower Anal-Genital Tract Carcinoma**

HPV E6 Human Papillomavirus (HPV) High-Risk E6/E7, RNA In Situ Hybridization

HPV L Human Papillomavirus (HPV) High/Low Risk, DNA In Situ Hybridization

HPV H Human Papillomavirus (HPV), High-Risk, DNA In Situ Hybridization

HPV L Human Papillomavirus (HPV), Low-Risk, DNA In Situ Hybridization

**Head and Neck**

FGF1F FGFR1 (8p11.2) Amplification, FISH, Tissue

HPV H Human Papillomavirus (HPV), High-Risk, DNA In Situ Hybridization

HPV L Human Papillomavirus (HPV), Low-Risk, DNA In Situ Hybridization

HPV T Human Papillomavirus (HPV) Typing, DNA In Situ Hybridization

MAMLF MAML2 (11q21) Rearrangement, Mucoepidermoid Carcinoma (MEC), FISH, Tissue

SGTF MYB (6q23) Rearrangement, FISH, Tissue

**Melanoma**

BRAFB Cell-Free DNA BRAF V600 Test, Blood

BRAFC BRAF Mutation Analysis (V600), Melanoma

KIT11 KIT Exon 11, Mutation Analysis

KIT13 KIT Exon 13, Mutation Analysis

KIT17 KIT Exon 17, Mutation Analysis

MELF Melanoma, FISH, Tissue

MELP Melanoma Targeted Gene Panel by Next-Generation Sequencing, Tumor

UMM3F Uveal Melanoma, Chromosome 3 Monosomy, FISH, Tissue

**Neuro-oncology**

GLIOF 1p/19q Deletion in Gliomas, FISH, Tissue

BRAFT BRAF Mutation Analysis (V600E), Tumor

CMAPT Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded

GCTF Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue

IDH12 IDH1/IDH2 Isocitrate Dehydrogenase 1 and 2 (IDH1/IDH2) Mutation Analysis, Tumor

MEDF Medulloblastoma, FISH, Tissue

MGMT MGMT Promoter Methylation, Tumor

NONTP Neuro-Oncology Panel, Tumor

TERT TERT Promoter Analysis, Tumor

**Pulmonary**

BRAFT BRAF Mutation Analysis (V600E), Tumor

EGFR T EGFR Gene, Mutation Analysis, 29 Mutation Panel, Tumor

FALKC ALK on Cytology Specimens, FISH

FGF1F FGFR1 (8p11.2) Amplification, FISH, Tissue

KRASO KRAS Mutation Analysis, 7 Mutation Panel, Other (Non-Colorectal)

LCAF Lung Cancer, ALK (2p23) Rearrangement, FISH, Tissue

EGFR Lung Cancer, EGFR with ALK Reflex, Tumor

LNGPR Lung Cancer-Targeted Gene Panel with Rearrangement, Tumor (mutations and rearrangements)

LUNGP Lung Cancer-Targeted Gene Panel, Tumor (mutations only)

LUNGR Lung Cancer Rearrangement Testing, Tumor (rearrangements only)

RETF Lung Cancer, RET (10q11) Rearrangement, FISH, Tissue

ROS1F Lung Cancer, ROS1 (6q22) Rearrangement, FISH, Tissue

METF MET (7q31), FISH, Tissue

**CELL-FREE DNA (cfDNA) TESTING**

BRAFB Cell-Free DNA BRAF V600 Test, Blood

EGFRD Cell-Free DNA EGFR Exon 18, 19, 20, 21, Mutation Analysis, Blood

T790M Cell-Free DNA EGFR T790M Mutation Analysis, Blood

KRASD Cell-Free DNA KRAS 12, 13, 61, 146, Blood

**ONCOLOGY: MOLECULAR DIAGNOSTIC TESTING**

**Gastrointestinal**

APCZ APC Gene, Full Gene Analysis

HCRC Hereditary Colon Cancer Multi-Gene Panel

MSIHC Microsatellite Instability (MSI)/ Immunohistochemistry (IHC) Profile-Lynch/ Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Screen

LYNCH Lynch Syndrome Panel

MLH1Z MLH1 Gene, Full Gene Analysis

MSH2Z MSH2 Gene, Full Gene Analysis

MSH6Z MSH6 Gene, Full Gene Analysis

MUTYH MUTYH Gene Analysis, Y165C and G382D

PMS2Z PMS2 Gene, Full Gene Analysis

U1A1V UDP-Glucuronosyl Transferase 1A1 TA Repeat Genotype, UGT1A1

UGTFG UDP-Glucuronosyl Transferase 1A1 (UGT1A1), Full Gene Sequencing

**Inherited Endocrine**

FMTT Familial Mutation, Targeted Testing

RETZ RET Proto-Oncogene, Full Gene Analysis

SDHP SDHB, SDHC, SDHD Gene Panel

VHLZ VHL Gene, Full Gene Analysis

## Patient Information (required)

Patient ID <i>(Medical Record No.)</i>	Client Account No.
Patient Name <i>(Last, First, Middle)</i>	Client Order No.
Birth Date <i>(Month DD, YYYY)</i>	

**PRIMARY BODY FLUID TESTS**

Tests for disease monitoring or aiding in the diagnosis

Bone and Soft Tissue

FGF23 Fibroblast Growth Factor 23 (FGF23), Plasma

Breast

C2729 Breast Carcinoma-Associated Antigen (CA 27.29), Serum

CA153 Cancer Antigen 15-3 (CA 15-3), Serum

Endocrine

Thyroid Cancer

CATLN Calcitonin, Fine-Needle Aspiration Biopsy (FNAB)-Needle Wash, Lymph Node

CATN Calcitonin, Serum

CEA Carcinoembryonic Antigen (CEA), Serum

TGMS Thyroglobulin Mass Spectrometry, Serum

HTGFN Thyroglobulin, Tumor Marker, Fine-Needle Aspiration (FNA)-Needle Wash, Lymph Node

HTGR Thyroglobulin, Tumor Marker Reflex to LC-MS/MS or Immunoassay

HTG2 Thyroglobulin, Tumor Marker, Serum

Neuroendocrine Tumors

CGAK Chromogranin A, Serum

GAST Gastrin, Serum

GLP Glucagon, Plasma

NSE Neuron-Specific Enolase (NSE), Serum

HPP Pancreatic Polypeptide, Plasma

VIP Vasoactive Intestinal Polypeptide (VIP), Plasma

Pituitary Tumors

ACTH Adrenocorticotropic Hormone (ACTH), Plasma

APGH Alpha-Subunit Pituitary Tumor Marker, Serum

FSH Follicle-Stimulating Hormone (FSH), Serum

HGH Growth Hormone, Serum

LH Luteinizing Hormone (LH), Serum

MCRPL Macroprolactin, Serum

NSE Neuron-Specific Enolase (NSE), Serum

PLPMA Prolactin, Pituitary Macroadenoma, Serum

PRL Prolactin, Serum

Biogenic Amines

CATU Catecholamine Fractionation, Free, 24 Hour, Urine

CATP Catecholamine Fractionation, Free, Plasma

HVA Homovanillic Acid (HVA), 24 Hour, Urine

HVAR Homovanillic Acid (HVA), Random, Urine

METAF Metanephrines, Fractionated, 24 Hour, Urine

PMET Metanephrines, Fractionated, Free, Plasma

METAR Metanephrines, Fractionated, Random, Urine

SERU Serotonin, 24 Hour, Urine

SERWB Serotonin, Blood

VH Vanillylmandelic Acid (VMA) and Homovanillic Acid (HVA), Random, Urine

VMA Vanillylmandelic Acid (VMA), 24 Hour, Urine

VMAR Vanillylmandelic Acid (VMA), Random, Urine

HIAA 5-Hydroxyindoleacetic Acid (5-HIAA), 24 Hour, Urine

Gastrointestinal

HIAA 5-Hydroxyindoleacetic Acid (5-HIAA), 24 Hour, Urine

L3AFP Alpha-Fetoprotein (AFP) L3% and Total, Hepatocellular Carcinoma Tumor Marker, Serum

AFPPT Alpha-Fetoprotein (AFP), Peritoneal Fluid

AFP Alpha-Fetoprotein (AFP) Tumor Marker, Serum

AMLPC Amylase, Pancreatic Cyst

199PC Carbohydrate Antigen 19-9 (CA 19-9), Pancreatic Cyst Fluid

199PT Carbohydrate Antigen 19-9 (CA 19-9), Peritoneal Fluid

CA19 Carbohydrate Antigen 19-9 (CA 19-9), Serum

CEAPC Carcinoembryonic Antigen (CEA), Pancreatic Cyst Fluid

CEAPT Carcinoembryonic Antigen (CEA), Peritoneal Fluid

CEA Carcinoembryonic Antigen (CEA), Serum

CGAK Chromogranin A, Serum

DCP Des-Gamma-Carboxy Prothrombin (DCP), Serum

FOBT Fecal Occult Blood, Colorectal Cancer Screen, Qualitative, Immunochemical

GAST Gastrin, Serum

GLP Glucagon, Plasma

NSE Neuron-Specific Enolase (NSE), Serum

HPP Pancreatic Polypeptide, Plasma

SERU Serotonin, 24 Hour, Urine

SERWB Serotonin, Blood

VIP Vasoactive Intestinal Polypeptide (VIP), Plasma

Genitourinary

AFPSF Alpha-Fetoprotein (AFP), Spinal Fluid

AFP Alpha-Fetoprotein (AFP) Tumor Marker, Serum

BHCG Beta-Human Chorionic Gonadotropin, Quantitative, Serum

BHSG Beta-Human Chorionic Gonadotropin, Quantitative, Spinal Fluid

CEASF Carcinoembryonic Antigen (CEA), Spinal Fluid

PSA Prostate-Specific Antigen (PSA) Diagnostic, Serum

SPSA Prostate-Specific Antigen (PSA) Screen, Serum

PHI1 Prostate Health Index (phi), Serum

PSAFT Prostate-Specific Antigen (PSA), Total and Free, Serum

Gynecology

BHCG Beta-Human Chorionic Gonadotropin, Quantitative, Serum

CA25 Cancer Antigen 125 (CA 125), Serum

HE4 Human Epididymis Protein 4, Serum

INHA Inhibin A, Tumor Marker, Serum

INHAB Inhibin A and B, Tumor Marker, Serum

INHB Inhibin B, Serum

ROMA Ovarian Malignancy Risk Algorithm

Pulmonary

PF199 Carbohydrate Antigen 19-9 (CA 19-9), Pleural Fluid

PFCEA Carcinoembryonic Antigen (CEA), Pleural Fluid

NSE Neuron-Specific Enolase (NSE), Serum

ADDITIONAL TESTS  
(INDICATE TEST CODE AND NAME)